Table 1.

Baseline demographic and disease characteristics.

CharacteristicsPlacebo, n = 48Baricitinib
1 mg, n = 272 mg, n = 294 mg, n = 268 mg, n = 24
Age, yrs48 (14)52 (12)53 (13)53 (9)53 (10)
Sex, % female8389866288
Duration of RA, yrs5 (4)5 (4)6 (5)5 (5)6 (5)
CCP-positive, %6363597346
RF-positive, %6756668575
MTX dose, mg/week15 (4)17 (4)15 (4)16 (5)16 (4)
Patients receiving prednisone, %5456625058
Tender joint count, 6821 (10)19 (9)27 (14)18 (12)23 (10)
Swollen joint count, 6614 (6)15 (6)18 (9)14 (6)16 (8)
DAS28-hsCRP5.5 (0.9)5.4 (0.8)5.6 (0.9)5.1 (1.0)5.7 (0.9)
HAQ-DI1.08 (0.64)1.24 (0.70)1.14 (0.68)0.99 (0.61)1.21 (0.61)
hsCRP, mg/l (ULN = 3 mg/l)20 (31)12 (12)15 (27)14 (22)14 (15)
ESR, mm/h40 (19)33 (18)32 (11)35 (18)40 (16)
Synovitis7.3 (5.8)6.7 (5.2)6.9 (5.6)6.7 (4.8)7.0 (5.0)
Osteitis6.5 (9.3)6.9 (8.0)6.4 (8.3)8.0 (11.3)4.9 (5.2)
Combined inflammation28.4 (22.8)27.1 (20.3)27.1 (22.7)28.2 (23.3)25.9 (17.5)
Bone erosion11.2 (8.4)12.8 (10.0)15.1 (15.8)11.7 (8.4)11.9 (11.5)
Cartilage loss10.3 (12.6)11.2 (16.5)13.1 (18.9)8.5 (11.6)9.1 (12.2)
Total joint damage37.0 (38.2)40.7 (48.7)48.0 (61.8)32.9 (35.7)34.6 (41.3)
  • Values are mean (SD) unless otherwise indicated. CCP: cyclic citrullinated peptide antibodies; DAS28-hsCRP: Disease Activity Score based on 28-joint count and level of high-sensitivity C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire–Disability Index; MTX: methotrexate; RA: rheumatoid arthritis; RF: rheumatoid factor; ULN: upper limit of normal.